Basic Neurosciences · Paper A
Lewy body / synucleinopathy
Naming the exact synucleinopathy matters because one timing rule separates two of its most similar-looking members, and antipsychotic prescribing safety depends on getting that name right. Take two patients with parkinsonism and dementia: one developed dementia before or within a year of the movement symptoms, the other many years after; that timing alone separates dementia with Lewy bodies from Parkinson's disease dementia.
Synucleinopathies are neurodegenerative disorders defined by abnormal clumps of alpha-synuclein protein, called Lewy bodies. They include Parkinson's disease, dementia with Lewy bodies (DLB), Parkinson's disease dementia, and multiple system atrophy. DLB's core features are fluctuating cognition, recurrent well-formed visual hallucinationsSeeing, hearing, or otherwise sensing things that are not really there.Read more → (seeing detailed things that are not there), spontaneous parkinsonism, and REM sleep behaviour disorder, which can predate dementia by years. NeurolepticAnother word for an antipsychotic drug.Read more → sensitivityThe proportion of people who truly have a condition that a test correctly identifies as positive.Read more →, a severe, sometimes life-threatening reaction to antipsychotics, is a key safety point, so antipsychotics are avoided or minimised, with cholinesterase inhibitors preferred instead. The 'one-year rule' separates DLB (dementia before or within a year of parkinsonism) from Parkinson's disease dementia (dementia more than a year after established motor disease). Take a patient with parkinsonism for five years who then develops dementia: that late timing points to Parkinson's disease dementia, not DLB. E.g., a patient with vivid visual hallucinations and cognitive fluctuation appearing before any parkinsonism strongly suggests DLB over Parkinson's disease dementia.
Getting the exact diagnosis right inside the synucleinopathy family is not an academic exercise: it changes which drug is safe to prescribe. Two patients can look almost identical, both with tremor, stiffness, and a failing memory, yet one may tolerate an antipsychotic reasonably well while the other could suffer a severe, sometimes fatal reaction to the very same tablet. Learning the timing rule that separates the main two conditions in this family is therefore a genuine patient-safety skill, not just an exam fact.
A synucleinopathy is a neurodegenerative disease caused by abnormal clumps of a protein called alpha-synuclein building up inside neurons, forming structures known as Lewy bodies. This family includes Parkinson's disease, dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and multiple system atrophy. All four share the same underlying rogue protein but differ in which brain regions are hit first and in what order the symptoms appear.
The caveat almost every learner trips on: DLB and PDD are, biologically, close to the same disease, and the ICD-11 and DSM-5 classification systems separate them purely on a timing rule, not on different underlying pathology. Treating them as unrelated diagnoses misses the point; the split exists mainly because it is clinically useful for predicting the course of illness and for planning safe prescribing, not because the diseases are fundamentally distinct entities under the microscope.
Alpha-synuclein is a normal protein in healthy neurons, thought to help regulate the release of (chemical messenger) at (the junctions between neurons). In synucleinopathies, it misfolds and aggregates into Lewy bodies, which are toxic to the neurons that contain them. Where these Lewy bodies accumulate first determines the first symptoms: starting in brainstem motor pathways gives parkinsonism (tremor, rigidity, slowness); spreading early into the cortex gives the fluctuating cognition and of DLB; spreading into the autonomic nervous system gives the blood-pressure and bladder problems of multiple system atrophy.
Suppose a 70-year-old develops shuffling gait and a resting tremor. If dementia develops before that motor disease has been present for a year, or within the same year, ICD-11 and DSM-5 both classify this as dementia with Lewy bodies. If instead the same patient has had well-established Parkinson's disease for, say, five years before dementia appears, the diagnosis is Parkinson's disease dementia instead: the 'one-year rule'. Core features that support a DLB diagnosis, beyond parkinsonism itself, are fluctuating cognition (good days and bad days, sometimes hour to hour), recurrent well-formed visual (detailed hallucinations, such as seeing people or animals that are not there), and REM sleep behaviour disorder (acting out dreams physically during REM sleep), which can precede the dementia by years and is a strong early clue.
Alzheimer's disease differs from Lewy body disease in both protein and pattern: Alzheimer's involves tau and amyloid rather than alpha-synuclein, and typically presents with early, prominent memory loss rather than early or fluctuating alertness. Delirium can mimic the fluctuating cognition of DLB, but delirium has an acute onset and an identifiable trigger such as infection, whereas DLB's fluctuations are a chronic, recurring feature of the underlying disease.
Diagnosis is clinical, built around the core features above plus supportive investigation. Dopamine transporter imaging (DaTscan) shows reduced uptake in the and helps confirm a Lewy body process when the clinical picture is uncertain. A careful sleep history looking for REM sleep behaviour disorder, and formal cognitive screening to characterise fluctuation, both support the diagnosis alongside imaging.
The single most important management point is antipsychotic avoidance: patients with DLB and PDD show severe , a reaction that can cause worsening rigidity, sedation, and, rarely, a life-threatening deterioration resembling neuroleptic malignant syndrome. When need treatment, a cautious low-dose atypical agent may occasionally be considered, but only under specialist guidance. Cholinesterase inhibitors, such as those recommended for Alzheimer's disease, are preferred and can help both cognition and psychiatric symptoms; this approach follows Maudsley Prescribing Guidelines and NICE dementia guidance (NG97).
When a question gives a timeline, always check whether dementia arrived before, within, or after a year of parkinsonism starting; that single detail decides DLB versus PDD, and the exam frequently hides it in a throwaway sentence about how long the patient has 'had Parkinson's'.
Same underlying alpha-synuclein pathology, split by timing: dementia within a year of parkinsonism is DLB, dementia after a year or more is PDD, and antipsychotics are dangerous in both.